Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL2354846 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL4920513 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL7537653 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL5679533 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL703430 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL509509 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL723498 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL2392102 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL37333 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL2350111 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024140596-A1 | SIRNA MOLECULE FOR REGULATING ACTIVITY OF XDH GENE | 大睿生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118063533-A | Modified nucleotide compound, oligonucleotide and application thereof | 广州必贝特医药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024092185-A1 | ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS | VIA NOVA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116917477-B | Targeting ligands containing N-acetylgalactosamine | 大睿生物医药科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |
| CN-117756790-A | Fluorescent probe with D-pi-A structure and preparation method and application thereof | 齐鲁工业大学(山东省科学院) | 2024-03-26 | — | — | CN | disclosed |
| CN-117756866-A | Targeting ligands containing N-acetylgalactosamine | 大睿生物医药科技(上海)有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003022815-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| EP-1213296-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0584611-B1 | Heteroaromatically condensed hydroxypyridone carboxamides, their preparation and use | BASF AG (DE) | 1996-01-17 | — | — | EP | disclosed |
| US-5354759-A | Angiotenin II antagonizing heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0584611-A1 | Heteroaromatically condensed hydroxypyridone carboxamides, their preparation and use | BASF Aktiengesellschaft (DE) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | TSHR 94/4885TDP1 4151/4885TP53 4712/4885 |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | TSHR 3870/4885TDP1 1484/4885TP53 1097/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | TSHR 4378/4885TDP1 275/4885TP53 2286/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | TSHR 96/4885TDP1 3915/4885TP53 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.